Building and Evolving a Chiral Control Strategy for Accelerated COVID Programs

已完结 10 由 musgs 发布于 2024/11/18 10:37:17

DOI:10.1021/acs.oprd.4c00392
作者：Christophe Allais, Aaron F. Baldwin, Hugh J. Clarke, Christina G. Connor, Michael Coutant, Cindy Duong, Michael Herr, Chintelle James, Maciej Kalinowski, Johnny W. Lee, Yizhou Liu, Jared L. Piper, Joh
文献类型：期刊论文
补充材料：只需要正文

American Chemical Society (ACS)

Abstract：The development of nirmatrelvir 1 (the active agent in PAXLOVID) was undertaken using a “lightspeed” paradigm to develop an oral antiviral treatment for SARS-CoV-2 (COVID-19). This paper des

应助信息

6小时前

lren

08183d2fa55611efb24a34735aa3bc31.pdf 已采纳

6小时前

Book学术机器人

2024/11/18 10:37:17 未找到该文献，机器人已退出，请等待人工下载

2024/11/18 10:37:17 Book学术AI机器人收到请求，开始寻找文献

2024/11/18 10:37:17 已向机器人发送请求

6小时前

musgs 发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:SpringerEffects of a large-scale bioretention installation on the species composition of an urban bird community as determined by passive acoustic monitoring